Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer

Gebbia, Vittorio; Bellavia, Maurizio; Banna, Giuseppe Luigi; Russo, Paolo di; Ferraú, Francesco; Tralongo, Paolo; Borsellino, Nicolò

doi:10.1016/j.cllc.2012.11.007

Cited by 47 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adherence rates of 80–95 % are generally considered as a minimum to obtain an optimal medication efficacy (Osterberg and Blaschke 2005; Ruddy et al 2009). Adherence <95 %, measured with the self-report Basel Assessment of Adherence Scale (BAAS), has previously been shown related to poorer rates of response to erlotinib (Gebbia et al 2013). The considerable number of patients (34.5 %) who had a PDC below 95 % confirms that medication adherence might be a relevant issue for this drug.…”

Section: Discussionmentioning

confidence: 99%

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

Timmers

Boons

Hove

et al. 2015

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

PurposeErlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-small cell lung cancer. Understanding actual use of medication is essential for optimizing treatment conditions.MethodsIn this multicentre prospective observational study, patients starting erlotinib treatment were followed for 4 months. Adherence was assessed using a medication event monitoring system (MEMS). Area under the curve (AUC) was determined after 1, 2 and 4 months. Before start and at monthly intervals, patients filled out questionnaires about attitude towards medication and disease, quality of life, symptoms and use in daily practice.ResultsSixty-two patients (median age 63.5 years, 53 % male) were included of whom 15 were still on treatment after 4 months. MEMS data of 55 patients revealed a mean adherence of 96.8 ± 4.0 %. Over one-third of patients had an adherence rate <95 %. At 1 month, 21 % of patients did not always correctly take erlotinib without food. Associated risk factors were older age, suboptimal adherence, ocular symptoms and stomatitis (all p < 0.05). After 1 month of treatment, fatigue (91 %) and rash (86 %) were the most common symptoms reported. AUCss of erlotinib was higher in patients with rash and patients with moderate–severe anorexia (both p < 0.05).ConclusionThough adherence to erlotinib treatment is generally high, non-adherence might be an issue in a considerable number of patients. To support optimal erlotinib intake, clinicians need to take adequate measures to ameliorate symptoms and to address adherence and correct intake without food. Especially older patients and those who experience stomatitis may need extra attention.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

Timmers

Boons

Hove

et al. 2015

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…OAM type was variable across studies and included capecitabine (Xeloda ® ), erlotinib (Tarceva ® ), exemestane (Aromasin ® ), gemcitabine (Gemzar ® ), imatinib (Gleevec ® ), sunitinib (Sutent ® ), tamoxifen (Nolvadex ® ), and temozolomide (Temodar ® ). Only two studies reported race, with the majority of those patients identifying as Caucasian (Gebbia et al, 2013; Schneider, Adams, & Gosselin, 2014). Ethnicity was not reported in any of the eight studies.…”

Section: Resultsmentioning

confidence: 99%

“…Two studies captured patient-reported OAM adherence using the Medication Adherence Rating Scale (MARS) (Timmers et al, 2014, 2015), whereas one employed the Basel Assessment of Adherence Scale (BAAS) (Gebbia et al, 2013). …”

Section: Resultsmentioning

confidence: 99%

“…MPR was calculated as the total days' supply of an OAM dispensed during a follow-up period, adjusted for dosage reductions (Addeo et al, 2015; Daouphars et al, 2013). The VAS ranged from 0 (no adherence) to 100 (perfect adherence) (Gebbia et al, 2013). MEMSCap recorded adherence through documenting each medication bottle opening as a dose (Timmers et al, 2015; Walter et al, 2013; Waterhouse, Calzone, Mele, & Brenner, 1993).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Association Between Patient-Reported and Objective Oral Anticancer Medication Adherence Measures: A Systematic Review

Atkinson¹,

Rodríguez²,

Gordon³

et al. 2016

ONF

View full text Add to dashboard Cite

Problem Identification Oral anticancer medication (OAM) use has been steadily increasing, leading to several patient benefits. A notable challenge for nurses is accurate monitoring of patient OAM regimens because nonadherence is associated with poor health outcomes and decreased survival. Currently, no gold standard measure of OAM adherence exists. The authors conducted a systematic review of the association between objective and patient-reported measures of OAM adherence. Literature Search A systematic electronic literature search was conducted using PubMed, EMBASE, Scopus, PsycINFO®, Cochrane Library, Web of Science, and CINAHL® databases through November 2014. Data Evaluation Articles were independently reviewed to determine whether they included an original characterization of the level of association between objective and patient-reported measures of OAM adherence. Synthesis From a total of 11,135 articles retrieved, eight studies met inclusion criteria. Objective adherence was primarily assessed using pill counts or Medication Event Monitoring System (MEMSCap™). Patient-reported adherence was most commonly assessed using study-specific questionnaires. Significant positive correlations were observed between objective and patient-reported adherence across most studies, with three studies reporting higher rates of adherence via patient reporting. Conclusions Despite variation in the OAMs and measures used, patient-reported adherence rates were equal to or higher than objective adherence measures across studies. Social desirability bias may be a concern; however, given the significant concordance observed, using patient-reported methods in future studies of OAM adherence may be justified. Implications for Nursing This review provides evidence to support nursing use of patient-reported measures to accurately monitor OAM adherence and potentially improve the quality of patient–provider communication.

show abstract

“…Type of side effects and failure of some patients to perceive benefits from biologic treatment may reduce adherence to oral biologic agent. Recent data have shown that an interventional program involving patients' caregivers results in an improved adherence to second-line erlotinib in a series of 150 patients with advanced non-small-cell lung cancer [73]. Adherence to erlotinib was lower in patients treated without a specifically designed educational program as compared with those treated after adequate education and identification of a specific caregiver.…”

Section: Adherence To Biologic Drugsmentioning

confidence: 95%

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

Gebbia

Bellavia

Ferraú

et al. 2011

Expert Opinion on Drug Safety

Self Cite

View full text Add to dashboard Cite

show abstract

Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer

Cited by 47 publications

References 27 publications

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

The Association Between Patient-Reported and Objective Oral Anticancer Medication Adherence Measures: A Systematic Review

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

Contact Info

Product

Resources

About